Owens & Minor, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States and internationally. It operates through two segments, Global Solutions and Global Products. The Global Solutions segment offers a portfolio of products and services to healthcare providers and manufacturers. Its portfolio of medical and surgical supplies includes branded products and its proprietary products. This segment also offers services to healthcare providers, which include supplier management, analytics, inventory management, and clinical supply management; and various programs to provide logistics and marketing solutions to its suppliers. The Global Products segment manufactures and sources medical surgical products for the prevention of healthcare-associated infections across the acute and alternate site channels. This segments products portfolio includes sterilization wraps, surgical drapes and gowns, facial protection products, protective apparel, medical exam gloves, custom and minor procedure kits, and other medical products. The company provides its products and services to multi-facility networks of healthcare providers, independent hospitals, surgery centers, physicians' practices, and networks of hospitals directly, as well as indirectly through third-party distributors. Owens & Minor, Inc. was founded in 1882 and is headquartered in Richmond, Virginia.
IPO Year:
Exchange: NYSE
Website: owens-minor.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/19/2024 | $24.00 → $19.00 | Neutral → Buy | Citigroup |
| 2/26/2024 | $24.00 | Market Perform | Leerink Partners |
| 1/3/2024 | $21.00 | Equal Weight | Barclays |
| 10/13/2022 | $52.00 → $18.00 | Buy → Neutral | Citigroup |
| 10/12/2022 | $43.00 → $17.00 | Buy → Underperform | BofA Securities |
| 10/12/2022 | $62.00 → $22.00 | Outperform → Neutral | Robert W. Baird |
| 4/26/2022 | $55.00 | Buy | Citigroup |
| 4/1/2022 | $43.00 | Neutral | Credit Suisse |
| 3/30/2022 | $46.00 | Underweight | JP Morgan |
| 2/28/2022 | $42.00 → $43.00 | Neutral | Credit Suisse |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)
10-Q - OWENS & MINOR INC/VA/ (0000075252) (Filer)
8-K - OWENS & MINOR INC/VA/ (0000075252) (Filer)
8-K - OWENS & MINOR INC/VA/ (0000075252) (Filer)
8-K - OWENS & MINOR INC/VA/ (0000075252) (Filer)
SD - OWENS & MINOR INC/VA/ (0000075252) (Filer)
8-K - OWENS & MINOR INC/VA/ (0000075252) (Filer)
10-Q - OWENS & MINOR INC/VA/ (0000075252) (Filer)
8-K - OWENS & MINOR INC/VA/ (0000075252) (Filer)
8-K - OWENS & MINOR INC/VA/ (0000075252) (Filer)
DEFA14A - OWENS & MINOR INC/VA/ (0000075252) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Citigroup upgraded Owens & Minor from Neutral to Buy and set a new price target of $19.00 from $24.00 previously
Leerink Partners initiated coverage of Owens & Minor with a rating of Market Perform and set a new price target of $24.00
Barclays initiated coverage of Owens & Minor with a rating of Equal Weight and set a new price target of $21.00
Citigroup downgraded Owens & Minor from Buy to Neutral and set a new price target of $18.00 from $52.00 previously
BofA Securities downgraded Owens & Minor from Buy to Underperform and set a new price target of $17.00 from $43.00 previously
Robert W. Baird downgraded Owens & Minor from Outperform to Neutral and set a new price target of $22.00 from $62.00 previously
Citigroup resumed coverage of Owens & Minor with a rating of Buy and set a new price target of $55.00
Credit Suisse resumed coverage of Owens & Minor with a rating of Neutral and set a new price target of $43.00
JP Morgan resumed coverage of Owens & Minor with a rating of Underweight and set a new price target of $46.00
Credit Suisse reiterated coverage of Owens & Minor with a rating of Neutral and set a new price target of $43.00 from $42.00 previously
Live Leadership Updates
NEW YORK, Sept. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 22, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space. Uber Technologies Inc. (NYSE:UBER) will replace Charter Communications Inc. (NASD: CHTR) in the S&P 100. Charter Communications will remain in the S&P 500.AppLovin Corp. (NASD: APP), Robinhood Markets Inc. (NASD: H
Gomez assumes leadership of Owens & Minor's people strategy with a focus on cultivating talent that supports company performance Owens & Minor, Inc. (NYSE:OMI), a leading global healthcare solutions company, today announced the appointment of Tammy Gomez as Executive Vice President & Chief Human Resources Officer, effective July 11, 2022. Gomez will report to Owens & Minor's President and Chief Executive Officer, Edward A. Pesicka, and be a member of the company's executive leadership team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220622005306/en/Owens & Minor names Tammy Gomez EVP and Chief Human Resources Officer, effect
This live feed shows all institutional transactions in real time.
SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)
SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)
SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)
SC 13G - OWENS & MINOR INC/VA/ (0000075252) (Subject)
SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)
SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)
SC 13G - OWENS & MINOR INC/VA/ (0000075252) (Subject)
SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)
SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)
SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)
Live finance-specific insights
Classified Products & Healthcare Services Segment as Discontinued Operations Continuing Operations, Patient Direct, Showed Solid Performance and Growth Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the second quarter ended June 30, 2025. In connection with a likely sale of the Company's Products & Healthcare Services segment, the results herein, unless otherwise noted, reflect the Company's continuing operations which primarily represent what was previously the Patient Direct segment and certain functional operations. "We are in the final stages of our robust process for the divestiture of the Products & Healthcare Services segment, and, as a result, have classif
Owens & Minor, Inc. (NYSE:OMI) plans to release financial results for the second quarter of 2025 on Monday, August 11, 2025, before trading begins on the New York Stock Exchange. The Company will host a conference call for investors and analysts at 8:30 a.m. EDT on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations/. A replay of the webcast
Top-Line Growth Led by the Patient Direct Segment Patient Direct Operating Margin Expanded by 173 Basis Points Company Reaffirmed 2025 Financial Guidance Remain Actively Engaged in Potential Sale of Products & Healthcare Services Segment Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the first quarter ended March 31, 2025. "Across the business we continued to see strong execution and progress towards our near and long-term strategies. Patient Direct delivered mid-single digit top-line growth with strong performance in nearly all therapy categories led by Diabetes and Sleep Supplies. The top-line growth combined with strong operational execution delivered mid-teen e
Owens & Minor, Inc. (NYSE:OMI) plans to release financial results for the first quarter of 2025 on Thursday, May 8, 2025, before trading begins on the New York Stock Exchange. The Company will host a conference call for investors and analysts at 8:00 a.m. EDT on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations/. A replay of the webcast can b
Total Debt Reduction of $244 Million in 2024, Capping a Two-Year Total Debt Reduction of $647 Million 2025 Guidance Midpoint Indicates Double-Digit Adjusted EBITDA & Adjusted EPS Growth, and Improving Cash Flow Active Discussions Well Underway Regarding Potential Sale of Products & Healthcare Services (P&HS) Segment Board of Directors Authorizes Share Repurchase Program of Up to $100 Million Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the fourth quarter and year ended December 31, 2024. "We are pleased with the progress that we have made against the strategy as outlined at our Investor Day in December 2023. As a reminder, we committed to optimizing our Prod
Expects to Report Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025 Owens & Minor, Inc. (NYSE:OMI) (the "Company") today announced selected preliminary financial results for the fourth quarter and year ended December 31, 2024 in advance of its upcoming earnings announcement and conference call. The release of the preliminary results relates to the Company's commencement of financing activity related to its previously announced agreement to acquire Rotech Healthcare Holdings, Inc ("Rotech"). "We are commencing a process to raise additional debt while the capital markets are attractive, to finance our previously announced agreement to acquire Rotech which we continu
Top-Line Growth Driven by Continued Solid Demand in Patient Direct and Medical Distribution Total Debt Reduction of Nearly $200 Million in the Third Quarter Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the third quarter ended September 30, 2024. Key Highlights: Consolidated revenue of $2.7 billion in the third quarter, representing year-over-year growth of 5% GAAP Net loss of $(13) million or $(0.17) per share, and adjusted earnings per share of $0.42 in the third quarter Adjusted EBITDA of $142 million in the third quarter, representing year-over-year growth of 5% $198 million in total debt reduction in the third quarter "Our third quarter results demons
Owens & Minor, Inc. (NYSE:OMI) plans to release financial results for the third quarter of 2024 on Monday, November 4, 2024, before trading begins on the New York Stock Exchange. The Company will host a conference call for investors and analysts at 8:30 a.m. ET on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations/. A replay of the webcast can
Top Line Expansion Driven by Solid Growth in Both Segments Second Quarter Operating Cash Flow of $116 Million Drove $71 million in Debt Reduction Expanding Patient Direct Segment with Agreement to Acquire Rotech Healthcare Holdings Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the second quarter ended June 30, 2024. Key Highlights: Consolidated revenue of $2.7 billion in the second quarter, representing year-over-year growth of 4% Net loss of $(32) million or $(0.42) per share in the second quarter Adjusted EBITDA of $127 million in the second quarter, representing year-over-year growth of 12% Doubled second quarter year over year Adjusted earnings
Plans to Release Full Results on Friday, August 2 Before the NYSE Open Owens & Minor, Inc. (NYSE:OMI) today announced selected preliminary financial results for the quarter ended June 30, 2024 as noted in the table below. The Company also reaffirmed its outlook for the full year 2024 as noted below in advance of its second quarter 2024 earnings announcement and conference call. Selected Preliminary Financial Results for the Quarter Ended June 30, 2024 (1) ($ in millions, except per share data) 2Q24 Revenue $2,651 - $2,671 Operating income, GAAP $16 - $20 Adj. Operating Income, Non-GAAP
Fastest customizable press release news feed in the world
NEW YORK, Sept. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 22, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space. Uber Technologies Inc. (NYSE:UBER) will replace Charter Communications Inc. (NASD: CHTR) in the S&P 100. Charter Communications will remain in the S&P 500.AppLovin Corp. (NASD: APP), Robinhood Markets Inc. (NASD: H
Classified Products & Healthcare Services Segment as Discontinued Operations Continuing Operations, Patient Direct, Showed Solid Performance and Growth Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the second quarter ended June 30, 2025. In connection with a likely sale of the Company's Products & Healthcare Services segment, the results herein, unless otherwise noted, reflect the Company's continuing operations which primarily represent what was previously the Patient Direct segment and certain functional operations. "We are in the final stages of our robust process for the divestiture of the Products & Healthcare Services segment, and, as a result, have classif
Owens & Minor, Inc. (NYSE:OMI) plans to release financial results for the second quarter of 2025 on Monday, August 11, 2025, before trading begins on the New York Stock Exchange. The Company will host a conference call for investors and analysts at 8:30 a.m. EDT on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations/. A replay of the webcast
OMI Remains Committed to Continued Growth in the Strong Home-based Care Market Will Focus on Deleveraging & Driving Profitable Growth Owens & Minor, Inc. (NYSE:OMI) today announced it has mutually agreed with Rotech Healthcare Holdings Inc. to terminate the previously announced acquisition. Under the terms of the merger agreement, Owens & Minor has paid $80 million to Rotech Healthcare. Owens & Minor will also redeem the $1 billion of notes issued in April 2025, which include a special mandatory redemption provision in accordance with their terms, and terminate the incremental term loan commitments and senior unsecured bridge loan commitments provided by our lenders which would have bee
Top-Line Growth Led by the Patient Direct Segment Patient Direct Operating Margin Expanded by 173 Basis Points Company Reaffirmed 2025 Financial Guidance Remain Actively Engaged in Potential Sale of Products & Healthcare Services Segment Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the first quarter ended March 31, 2025. "Across the business we continued to see strong execution and progress towards our near and long-term strategies. Patient Direct delivered mid-single digit top-line growth with strong performance in nearly all therapy categories led by Diabetes and Sleep Supplies. The top-line growth combined with strong operational execution delivered mid-teen e
Owens & Minor, Inc. (NYSE:OMI) plans to release financial results for the first quarter of 2025 on Thursday, May 8, 2025, before trading begins on the New York Stock Exchange. The Company will host a conference call for investors and analysts at 8:00 a.m. EDT on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations/. A replay of the webcast can b
Transformative investments in technology, automation and analytics capabilities will help improve supply chain visibility and resiliency for Products & Healthcare Services customers and lay the foundation for future innovations Owens & Minor, Inc. (NYSE:OMI) today announced important milestones in advancing the medical distribution capabilities of its Products & Healthcare Services (P&HS) business segment, which provides essential products and services to thousands of healthcare customers. These milestones are the result of recent company investments in new technology, automation and analytics capabilities geared specifically toward driving greater efficiencies for the P&HS segment and imp
Owens & Minor, Inc. (NYSE:OMI) (the "Company") announced today the upsize and pricing of its private offering (the "Offering") of $1 billion aggregate principal amount of its 10.000% senior secured notes due 2030 (the "Notes"). The Offering is expected to close on April 4, 2025, subject to customary closing conditions. The Notes will bear interest at the rate of 10.000% per year. The Notes will mature on April 15, 2030 (subject to certain earlier maturity triggers). The Notes were offered at a price of 100% of their principal amount. Unless the previously announced acquisition (the "Acquisition") of Rotech Healthcare Holdings Inc. ("Rotech") is consummated substantially concurrently with t
Owens & Minor, Inc. (NYSE:OMI) (the "Company") announced today that it has launched a private offering (the "Offering") of $600 million aggregate principal amount of senior secured notes due 2030 (the "Notes"), subject to customary and market conditions. Unless the previously announced acquisition (the "Acquisition") of Rotech Healthcare Holdings Inc. ("Rotech") is consummated concurrently with or promptly following the closing of the Offering, the Company will deposit the gross proceeds from the Offering into a segregated escrow account until the date that certain escrow release conditions, including the consummation of the Acquisition, have been satisfied. The consummation of the Acquisi
Total Debt Reduction of $244 Million in 2024, Capping a Two-Year Total Debt Reduction of $647 Million 2025 Guidance Midpoint Indicates Double-Digit Adjusted EBITDA & Adjusted EPS Growth, and Improving Cash Flow Active Discussions Well Underway Regarding Potential Sale of Products & Healthcare Services (P&HS) Segment Board of Directors Authorizes Share Repurchase Program of Up to $100 Million Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the fourth quarter and year ended December 31, 2024. "We are pleased with the progress that we have made against the strategy as outlined at our Investor Day in December 2023. As a reminder, we committed to optimizing our Prod